AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16504531 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 30
Study 12040966 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruscus extract (Fagorutin Ruscus Kapseln)
Number of subjects: 166
Study 12040966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 11189407 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha-2b
Number of subjects: 29
Study 7583751 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia campaign promoting public action to help maltreated children
Number of subjects: 0
Study 7583751 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia campaign exposure
Number of subjects: 0
Study 7583751 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia campaign regarding alcohol and other drug abuse
Number of subjects: 0
Study 7583751 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia campaign regarding at-risk children
Number of subjects: 0
Study 2517626 — intervention group
Group type: EXPERIMENTAL
Intervention: 41% BCAA solution
Number of subjects: 2
Study 2517626 — intervention group
Group type: COMPARATOR
Intervention: 23% BCAA solution
Number of subjects: 2
Study 605356 — intervention group
Group type: EXPERIMENTAL
Intervention: Propantheline (30 mg)
Number of subjects: 8
Study 605356 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hyoscyamine (0.8 mg)
Number of subjects: 8
Study 605356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30096579 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program (6-week duration)
Number of subjects: 104
Study 30096579 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 104
Study 27418685 — intervention group
Group type: EXPERIMENTAL
Intervention: PAH drug treatment in inoperable CTEPH
Number of subjects: 42
Study 27418685 — intervention group
Group type: COMPARATOR
Intervention: PAH drug treatment in operable CTEPH
Number of subjects: 42
Study 24287500 — intervention group
Group type: EXPERIMENTAL
Intervention: T280M variant (rs3732378)
Number of subjects: 3642
Study 24287500 — intervention group
Group type: EXPERIMENTAL
Intervention: rs2853707
Number of subjects: 3642
Study 24287500 — intervention group
Group type: EXPERIMENTAL
Intervention: rs12636547
Number of subjects: 3642
Study 24287500 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1877563
Number of subjects: 3642
Study 24287500 — intervention group
Group type: EXPERIMENTAL
Intervention: rs11715522
Number of subjects: 3642
Study 24287500 — intervention group
Group type: EXPERIMENTAL
Intervention: rs2669845
Number of subjects: 3642
Study 24287500 — intervention group
Group type: EXPERIMENTAL
Intervention: rs9868689
Number of subjects: 3642
Study 22764744 — intervention group
Group type: EXPERIMENTAL
Intervention: IB1001 75 IU kg(‐1)
Number of subjects: 32
Study 22764744 — intervention group
Group type: COMPARATOR
Intervention: nonacog alfa
Number of subjects: 32
Study 22764744 — intervention group
Group type: EXPERIMENTAL
Intervention: IB1001
Number of subjects: 32
Study 20418724 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-selected treatment partner-assisted therapy (TPA)
Number of subjects: 499
Study 20418724 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 499
Study 18752863 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin therapy
Number of subjects: 368
Study 16043684 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-positive patients (n = 40)
Number of subjects: 302
Study 16043684 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture-negative patients (n = 14)
Number of subjects: 302
Study 16043684 — intervention group
Group type: COMPARATOR
Intervention: Controls (n = 243)
Number of subjects: 302
Study 12511452 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast feeding
Number of subjects: 180
Study 12511452 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% glucose plus pacifier
Number of subjects: 180
Study 12511452 — intervention group
Group type: COMPARATOR
Intervention: Held in mother's arms
Number of subjects: 180
Study 12511452 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 ml of sterile water)
Number of subjects: 180
Study 10493684 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-deteriorated cartilage areas
Number of subjects: 16
Study 10493684 — intervention group
Group type: EXPERIMENTAL
Intervention: Deteriorated cartilage areas
Number of subjects: 16
Study 10493684 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NO levels in HOA patients
Number of subjects: 16
Study 10493684 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NO levels in ambulatory HOA patients
Number of subjects: 16
Study 10493684 — intervention group
Group type: COMPARATOR
Intervention: Serum NO levels in healthy volunteers
Number of subjects: 16
Study 8941409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (75 mg/m2) and paclitaxel (135 mg/m2)
Number of subjects: 386
Study 8941409 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (75 mg/m2) and cyclophosphamide (750 mg/m2)
Number of subjects: 386
Study 1780171 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine, 30 mg/kg in divided doses; Praziquantel, 40 mg/kg
Number of subjects: 0
Study 1780171 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of infected schoolchildren (Area S)
Number of subjects: 0
Study 1780171 — intervention group
Group type: COMPARATOR
Intervention: Treatment of individuals excreting >=800 epg (Area W)
Number of subjects: 0
Study 1780171 — intervention group
Group type: COMPARATOR
Intervention: Treatment of individuals excreting >=100 epg (Area H)
Number of subjects: 0
Study 7298119 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (800 mEq/day)
Number of subjects: 8
Study 7298119 — intervention group
Group type: COMPARATOR
Intervention: Low sodium intake (10 mEq/day)
Number of subjects: 8
Study 30266329 — intervention group
Group type: EXPERIMENTAL
Intervention: aP(PTgen/FHA)
Number of subjects: 450
Study 30266329 — intervention group
Group type: EXPERIMENTAL
Intervention: TdaP(PTgen/FHA)
Number of subjects: 450
Study 30266329 — intervention group
Group type: COMPARATOR
Intervention: Tdap (comparator)
Number of subjects: 450
Study 26395129 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Shilajit (250 mg twice a day for 90 days)
Number of subjects: 0
Study 26395129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24852468 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU) treatment with total fluence of 150-180 J/cm
Number of subjects: 0
Study 24852468 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU) treatment
Number of subjects: 0
Study 22513659 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g per kg per day alanyl-glutamine
Number of subjects: 174
Study 22513659 — intervention group
Group type: COMPARATOR
Intervention: isonitrogenous isocaloric parenteral nutrition
Number of subjects: 174
Study 20226646 — intervention group
Group type: EXPERIMENTAL
Intervention: e-MiniAQLQ
Number of subjects: 40
Study 20226646 — intervention group
Group type: COMPARATOR
Intervention: p-MiniAQLQ
Number of subjects: 40
Study 18549913 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxypurinol (600 mg/day)
Number of subjects: 405
Study 18549913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 15772318 — intervention group
Group type: EXPERIMENTAL
Intervention: SP + CQ
Number of subjects: 280
Study 15772318 — intervention group
Group type: COMPARATOR
Intervention: SP
Number of subjects: 280
Study 12203176 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment program
Number of subjects: 0
Study 12203176 — intervention group
Group type: COMPARATOR
Intervention: Secular trend
Number of subjects: 0
Study 10893069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinemia
Number of subjects: 116
Study 10893069 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T mutation
Number of subjects: 116
Study 10893069 — intervention group
Group type: EXPERIMENTAL
Intervention: Young patients (age < 50 years)
Number of subjects: 116
Study 8964276 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 100 mg (LTG 100)
Number of subjects: 343
Study 8964276 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg (LTG 200)
Number of subjects: 343
Study 8964276 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine 600 mg (CBZ 600)
Number of subjects: 343
Study 2056904 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2% glucose polymer‐electrolyte beverage (GP)
Number of subjects: 49
Study 2056904 — intervention group
Group type: COMPARATOR
Intervention: Flavored sweetened placebo drink (SP)
Number of subjects: 49
Study 2056904 — intervention group
Group type: COMPARATOR
Intervention: Tap water (TW)
Number of subjects: 49
Study 7046680 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training program
Number of subjects: 42
Study 7046680 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 42
Study 31332820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 30 mg
Number of subjects: 48
Study 31332820 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 80 mg
Number of subjects: 48
Study 31332820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 20 mg followed by 10 mg once daily for 2 days
Number of subjects: 48
Study 31332820 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg twice daily for 3 days
Number of subjects: 48
Study 31332820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole infusion
Number of subjects: 48
Study 27534671 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate therapy
Number of subjects: 157
Study 26821931 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide plus low-dose dexamethasone (Rd)
Number of subjects: 80
Study 24957533 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned delivery at 37 weeks (group A)
Number of subjects: 76
Study 24957533 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (group B)
Number of subjects: 76
Study 22354905 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressively reduced nicotine content cigarettes
Number of subjects: 135
Study 22354905 — intervention group
Group type: COMPARATOR
Intervention: Control group (smoked their own brand of cigarettes)
Number of subjects: 135
Study 20808204 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (1.5 mg/kg per day for 2 weeks then 0.75 mg/kg per day for 2 weeks)
Number of subjects: 110
Study 20808204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 20808204 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 110
Study 17287417 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (Avandia, 4 mg twice a day)
Number of subjects: 30
Study 17287417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15639724 — intervention group
Group type: EXPERIMENTAL
Intervention: First line therapy with carboplatin and paclitaxel
Number of subjects: 230
Study 15639724 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 230
Study 15639724 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline performance status
Number of subjects: 230
Study 15639724 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-squamous histology
Number of subjects: 230
Study 15639724 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 230
Study 15639724 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more cycles of therapy
Number of subjects: 230
Study 15639724 — intervention group
Group type: EXPERIMENTAL
Intervention: Four or more cycles of therapy
Number of subjects: 230
Study 15639724 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 2 or greater neuropathy
Number of subjects: 230
Study 14592237 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological dose of melatonin (0.14 mg)
Number of subjects: 1
Study 14592237 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraphysiological dose of melatonin (2.2 mg)
Number of subjects: 1
Study 14592237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 9988788 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (estradiol valerate 2 mg/day)
Number of subjects: 60
Study 9988788 — intervention group
Group type: COMPARATOR
Intervention: Cyclic estrogen/sequential progestogen regimen
Number of subjects: 60
Study 9988788 — intervention group
Group type: COMPARATOR
Intervention: Continuous estrogen/sequential progestogen regimen
Number of subjects: 60
Study 7901531 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN alpha) treatment
Number of subjects: 5
Study 3315272 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-24 once-daily at 1500 hr
Number of subjects: 8
Study 3315272 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-24 once-daily at 2100 hr
Number of subjects: 8
Study 3315272 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-24 treatment (irrespective of dosing time)
Number of subjects: 8
Study 3315272 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-24 dosing at 1500 or 2100 hr
Number of subjects: 8
Study 3315272 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-24 at 1500 hr
Number of subjects: 8
Study 3315272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31530653 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Consent process
Number of subjects: 60
Study 30032940 — intervention group
Group type: COMPARATOR
Intervention: EMA + Dashboard (self-directed condition)
Number of subjects: 34
Study 30032940 — intervention group
Group type: COMPARATOR
Intervention: EMA + Dashboard + Counselor (counselor-supported condition)
Number of subjects: 34
Study 27474885 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein Pasta (16 g protein, 6 g fiber)
Number of subjects: 36
Study 27474885 — intervention group
Group type: EXPERIMENTAL
Intervention: High Fiber Pasta (11 g protein, 8 g fiber)
Number of subjects: 36
Study 27474885 — intervention group
Group type: COMPARATOR
Intervention: Control Pasta (11 g protein, 6 g fiber)
Number of subjects: 36
Study 27474885 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein Pasta
Number of subjects: 36
Study 27474885 — intervention group
Group type: EXPERIMENTAL
Intervention: High Fiber Pasta
Number of subjects: 36
Study 27474885 — intervention group
Group type: COMPARATOR
Intervention: Control Pasta
Number of subjects: 36
Study 24508492 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MR‐proADM concentrations
Number of subjects: 7863
Study 24508492 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in MR‐proADM after one year
Number of subjects: 7863
Study 24508492 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in MR‐proADM
Number of subjects: 7863
Study 23149928 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxybupropion concentrations (per μg/ml)
Number of subjects: 0
Study 23149928 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion levels
Number of subjects: 0
Study 23149928 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion dosing to achieve hydroxybupropion level of 0.7 μg/ml
Number of subjects: 0
Study 20735794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuning in to Kids parenting program (6 sessions + 2 booster sessions)
Number of subjects: 216
Study 20735794 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 216
Study 18614723 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise performed 17 h before high-sugar-food ingestion
Number of subjects: 13
Study 18614723 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 13
Study 15678250 — intervention group
Group type: EXPERIMENTAL
Intervention: HR (0‐[beta‐hydroxyethyl]‐rutosides) 2 g/day for 8 weeks
Number of subjects: 90
Study 15678250 — intervention group
Group type: COMPARATOR
Intervention: D+H (diosmin+hesperidin) 500 mg tablet 3 times daily for 8 weeks
Number of subjects: 90
Study 12071235 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretic application of lidocaine (60 mg)
Number of subjects: 0
Study 12071235 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lidocaine (40 mg)
Number of subjects: 0
Study 10072218 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindoprilat
Number of subjects: 25
Study 10072218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 10072218 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindoprilat (in LV dysfunction subgroup)
Number of subjects: 25
Study 10072218 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindoprilat (in normal LV function subgroup)
Number of subjects: 25
Study 8909084 — intervention group
Group type: EXPERIMENTAL
Intervention: Aftercare group therapy during inpatient treatment
Number of subjects: 26
Study 8909084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with aftercare orientation and treatment contract
Number of subjects: 26
Study 6353431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin
Number of subjects: 138
Study 6353431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin
Number of subjects: 138
Study 30306334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-anchored maxillary protraction therapy (BAMP) for 18 months
Number of subjects: 18
Study 28933876 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant iron-deficient anemia (IDA)
Number of subjects: 873
Study 28933876 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited caregiver responsiveness and stimulation
Number of subjects: 873
Study 28933876 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer rejection at age 10
Number of subjects: 873
Study 24870830 — intervention group
Group type: EXPERIMENTAL
Intervention: News stories that mention alcohol as a causative factor
Number of subjects: 60
Study 24870830 — intervention group
Group type: COMPARATOR
Intervention: News stories that do not mention alcohol as a causative factor
Number of subjects: 60
Study 25163547 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological mesh closure of the pelvic floor after eAPR
Number of subjects: 104
Study 25163547 — intervention group
Group type: COMPARATOR
Intervention: Primary perineal wound closure
Number of subjects: 104
Study 22575355 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50mg)
Number of subjects: 128
Study 22575355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 19944917 — intervention group
Group type: EXPERIMENTAL
Intervention: Platica (small-group discussions led by a health promoter)
Number of subjects: 231
Study 19944917 — intervention group
Group type: COMPARATOR
Intervention: Media (culturally tailored mailer)
Number of subjects: 231
Study 17242632 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d) for 7 days starting 1 week after surgery
Number of subjects: 10
Study 17242632 — intervention group
Group type: COMPARATOR
Intervention: Control (no raloxifene)
Number of subjects: 10
Study 15342900 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (12 mg, 2 doses, intramuscular injection, 24 hours apart)
Number of subjects: 223
Study 15342900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 11434939 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% once daily (QD)
Number of subjects: 1198
Study 11434939 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% twice daily (BID)
Number of subjects: 1198
Study 11434939 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily (BID)
Number of subjects: 1198
Study 11434939 — intervention group
Group type: COMPARATOR
Intervention: Bimatoprost QD vs Timolol
Number of subjects: 1198
Study 9884940 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified in vitro method 1
Number of subjects: 30
Study 9884940 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified in vitro method 2
Number of subjects: 30
Study 9884940 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro method
Number of subjects: 30
Study 9884940 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro labeled RBCs through Hickman catheters
Number of subjects: 30
Study 10411845 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 472
Study 10411845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study 10411845 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin vs Placebo
Number of subjects: 472
Study 2192554 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide hydrochloride (Imodium A‐D)
Number of subjects: 0
Study 2192554 — intervention group
Group type: COMPARATOR
Intervention: Attapulgite (Diasorb)
Number of subjects: 0
Study 32949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispaghula husk
Number of subjects: 12
Study 32949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam, Hyoscine butylbromide, Ispaghula husk (all three agents)
Number of subjects: 12
Study 32949 — intervention group
Group type: EXPERIMENTAL
Intervention: One or two of the potent preparations (Lorazepam, Hyoscine butylbromide, Ispaghula husk)
Number of subjects: 12
Study 32949 — intervention group
Group type: COMPARATOR
Intervention: Dummy preparations (control)
Number of subjects: 12
Study 31120381 — intervention group
Group type: EXPERIMENTAL
Intervention: Contacted by the social worker
Number of subjects: 172
Study 31120381 — intervention group
Group type: EXPERIMENTAL
Intervention: Social worker assistance
Number of subjects: 172
Study 28219917 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate (ISDN)
Number of subjects: 44
Study 28219917 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate + Hydralazine (ISDN+hydral)
Number of subjects: 44
Study 28219917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 25588441 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-sterile clean boxed gloves
Number of subjects: 493
Study 25588441 — intervention group
Group type: COMPARATOR
Intervention: Sterile gloves
Number of subjects: 493
Study 23785451 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive sexual risk intervention
Number of subjects: 584
Study 23785451 — intervention group
Group type: COMPARATOR
Intervention: Didactic sexual risk intervention
Number of subjects: 584